You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of an adipose-derived stem cell isolation matrix
SBC: AFFINERGY, LLC Topic: NIGMSDESCRIPTION (provided by applicant): Approximately 500,000 bone-grafting procedures are performed each year in the United States. Autologous iliac crest bone graft continues to be the gold standard, because it provides essential elements for bone formation: progenitor cells, an osteoconductive matrix, and osteoinductive molecules. However, iliac crest harvest is associated with a significant numbe ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Bioactive Peptide Coatings for Synthetic Bone Grafts
SBC: AFFINERGY, LLC Topic: NIGMSDESCRIPTION (provided by applicant): Back pain is one of the leading reasons for physician visits in the United States and in many cases requires surgical intervention. In the United States, there are over 500,000 spinal fusion surgeries every year, and the frequency of these surgeries is projected to grow 6% per year. The gold standard for bone graft in spinal fusion is autograft from the iliac c ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Delivery of Adipose Derived Stem Cells for Healing Surgical Hernia Repairs
SBC: AFFINERGY, LLC Topic: NIGMSDESCRIPTION (provided by applicant): Over 700,000 surgical hernia repairs are performed each year in the United States and despite recent advances, a significant rate of recurrence persists. Of these surgeries, 100,000 are for incisional or visceral herniarepairs, which cost 1.7B annually and have a recurrence rate that can be up to 60%. The incorporation of biocompatible mesh to strengthen the ab ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Lab-on-a-Chip for Multiplexed Newborn Screening of Lysosomal Storage Disorders
SBC: ADVANCED LIQUID LOGIC Topic: NICHDDESCRIPTION (provided by applicant): Newborn screening is currently performed by collecting dried bloodspots from infants and then sending them to a lab for analysis. It is primarily performed to detect disorders which lead to severe physical and mental disabilities. There is an increasing necessity to screen for a number of lysosomal storage disorders for which therapies are becoming available. T ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Middle School Media Literacy for Reproductive Health
SBC: Innovation Research And Training, Inc. Topic: NICHDDESCRIPTION (provided by applicant): Consumption of unhealthy media messages that normalize or glorify risky sex is related to early and risky sexual behaviors in adolescents. Critical analysis of these media messages promotes healthy perspective-taking about relationships and sexual behaviors. The proposed project will complete the development of Media World Relationships, a prevention program th ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
ABLE Kids II- Advanced Biofidelic Lower Extremity Kids Prosthesis II
SBC: ORTHOCARE INNOVATIONS LLC Topic: NICHDDESCRIPTION (provided by applicant): The Advanced Biofidelic Lower Extremity Kids prosthesis (ABLE Kids) project will advance the state-of-the-art of pediatric prosthesis systems by advancing the demonstrably successful Phase I device and refining it intoan ultracompact and lightweight form factor suitable for pediatric use. Through the support of the Shriner's Hospitals in Salt Lake City, U ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Computerized Orthotic Prescription System- COPS
SBC: ORTHOCARE INNOVATIONS LLC Topic: NICHDDESCRIPTION (provided by applicant): Stiffness and alignment of ankle-foot orthoses (AFOs) should be tuned optimally to maximize their function. Improperly tuned AFO may induce joint pain, reduced ambulatory function, and increased medical complications for patients with stroke. Therefore, the relative quality of AFOs fit determined by its stiffness and alignment is of paramount concern in the d ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Silicone-free glass pre-filled syringe system for Biological Drugs.
SBC: TRIBOFILM RESEARCH INC Topic: NHLBIDESCRIPTION: In the medical device industry, silicone oil is a ubiquitous lubricant used in the manufacture, assembly of medical components, and also as the terminal lubricant for proper device operation. In prefilled syringes, problems arise when micro-droplets of silicone oil migrate into the drug medium and act as a contaminant which can potentially react with the packaged drug. In the case of ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Novel antithrombotic agents to prevent hemodialysis vascular access failure
SBC: EVAS THERAPEUTICS LLC Topic: NHLBIDESCRIPTION (provided by applicant): Currently, more than 60 % of end-stage renal diseases patients who require chronic hemodialysis are accessed through a native arteriovenous fistula (AVF) or synthetic graft (AVG). Unfortunately, primary failure rates were as high as 60 % at 6 months after AVF creation and 77% at 1 year after AVG construction. Surgical trauma, repeated needle punctures, mechani ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Development of an Anti-P-selectin Antibody for the Treatment of Sickle Cell Disea
SBC: SELEXYS PHARMACEUTICALS CORPORATION Topic: NHLBIDESCRIPTION (provided by applicant): Selexys Pharmaceuticals is developing a humanized monoclonal antibody drug called SelG1 directed against P-selectin for the treatment of vasoocclusive crisis in patients with sickle cell disease. The ultimate goal of this Phase IIB proposal is to further advance SelG1 into Phase II/III safety and efficacy trials to support of regulatory filings for FDA approval ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health